Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2101 to 2115 of 8213 results

  1. Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]

    In development Reference number: GID-TA11584 Expected publication date:  08 December 2027

    Technology appraisal guidance
    In development

  2. Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891]

    In development Reference number: GID-TA11473 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]

    Awaiting development Reference number: GID-TA11438 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]

    Awaiting development Reference number: GID-TA11428 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]

    Awaiting development Reference number: GID-TA11360 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]

    Awaiting development Reference number: GID-TA11284 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Sulthiame for treating self-limiting epilepsy with centrotemporal spikes in children TSID 12106

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]

    In development Reference number: GID-TA11554 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Diltiazem (Anatop, SLV-324, VEN 307) for Anal fissure [TSID 12100]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Doravirine–islatravir for treating HIV-1 in people with virological suppression on bictegravir, emtricitabine and tenofovir alafenamide combination treatment [TSID12171]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Doravirine-islatravir for previously untreated HIV-1 infection [TSID12172]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Doravirine–islatravir for treating HIV-1 in people with virological suppression on antiretroviral therapy [TSID12173]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Orforglipron for treating type 2 diabetes [TSID12130]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Mosunetuzumab for treating relapsed or refractory follicular lymphoma [TSID 12081]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation